Latigo Biotherapeutics, Inc. has granted stock options to its Chief Financial Officer, Neha Krishnamohan, as part of its strategy to align executive interests with those of its shareholders. This significant move, reported in a recent SEC filing, highlights the company's commitment to retaining key talent in a competitive market.

Background

Latigo Biotherapeutics, Inc. operates within the pharmaceutical preparations sector, classified under SIC 2834. The company is publicly traded on the Nasdaq under the ticker symbol LTGO. Latigo focuses on developing innovative therapies, and its recent filings indicate an active engagement in the market, including a range of SEC submissions.

What the Filing Says

According to the SEC filing dated November 18, 2026, Krishnamohan was granted an employee stock option to purchase 175,000 shares of common stock at an exercise price of $13.11 per share. The options are structured to vest over a period, with 25% of the shares vesting on March 31, 2027, another 25% on November 3, 2027, and the remaining 50% on May 3, 2028.

Impact

This stock option grant may positively impact Latigo Biotherapeutics by incentivizing Krishnamohan to drive the company's growth and performance. It reflects a broader trend in the pharmaceutical industry where companies aim to retain top talent amid increasing competition. The decision may also resonate with investors who favor alignment between executive compensation and shareholder value.

What's Next

The filing does not specify what happens next regarding further corporate actions or additional filings.